Literature DB >> 26216968

Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.

Andrew D Skora1, Jacqueline Douglass2, Michael S Hwang2, Ada J Tam3, Richard L Blosser3, Sandra B Gabelli4, Jianhong Cao5, Luis A Diaz2, Nickolas Papadopoulos2, Kenneth W Kinzler2, Bert Vogelstein6, Shibin Zhou7.   

Abstract

Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We here describe an approach to identify single-chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by HLA molecules. We demonstrate that these scFvs can be successfully converted to full-length antibodies, termed MANAbodies, targeting "Mutation-Associated Neo-Antigens" bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for mutant peptides bound to predefined HLA types. In this way, we obtained two scFvs, one specific for a peptide encoded by a common KRAS mutant and the other by a common epidermal growth factor receptor (EGFR) mutant. The scFvs bound to these peptides only when the peptides were complexed with HLA-A2 (KRAS peptide) or HLA-A3 (EGFR peptide). We converted one scFv to a full-length antibody (MANAbody) and demonstrate that the MANAbody specifically reacts with mutant peptide-HLA complex even when the peptide differs by only one amino acid from the normal, WT form.

Entities:  

Keywords:  antibody engineering; immunotherapy; oncogene; personalized; therapy

Mesh:

Substances:

Year:  2015        PMID: 26216968      PMCID: PMC4538619          DOI: 10.1073/pnas.1511996112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Flow cytometry: a versatile tool for all phases of drug discovery.

Authors: 
Journal:  Drug Discov Today       Date:  1999-04       Impact factor: 7.851

Review 2.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

3.  An integrated approach to extreme thermostabilization and affinity maturation of an antibody.

Authors:  Audrey D McConnell; Vladimir Spasojevich; John L Macomber; Irina P Krapf; Andy Chen; Joseph C Sheffer; Ashley Berkebile; Robert A Horlick; Steven Neben; David J King; Peter M Bowers
Journal:  Protein Eng Des Sel       Date:  2012-11-19       Impact factor: 1.650

4.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

5.  Off-rate screening for selection of high-affinity anti-drug antibodies.

Authors:  Francisco Ylera; Stefan Harth; Dirk Waldherr; Christian Frisch; Achim Knappik
Journal:  Anal Biochem       Date:  2013-07-29       Impact factor: 3.365

Review 6.  Mutant ras epitopes as targets for cancer vaccines.

Authors:  S I Abrams; P H Hand; K Y Tsang; J Schlom
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

Review 7.  Therapeutic strategies for inhibiting oncogenic BRAF signaling.

Authors:  Ensar Halilovic; David B Solit
Journal:  Curr Opin Pharmacol       Date:  2008-08-03       Impact factor: 5.547

8.  Beyond natural antibodies: the power of in vitro display technologies.

Authors:  Andrew R M Bradbury; Sachdev Sidhu; Stefan Dübel; John McCafferty
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908

9.  Structural consensus among antibodies defines the antigen binding site.

Authors:  Vered Kunik; Bjoern Peters; Yanay Ofran
Journal:  PLoS Comput Biol       Date:  2012-02-23       Impact factor: 4.475

10.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

View more
  18 in total

1.  QnAs with Kenneth W. Kinzler.

Authors:  Sandeep Ravindran
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 11.205

2.  A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation.

Authors:  Rahel Frick; Lene S Høydahl; Jan Petersen; M Fleur du Pré; Shraddha Kumari; Grete Berntsen; Alisa E Dewan; Jeliazko R Jeliazkov; Kristin S Gunnarsen; Terje Frigstad; Erik S Vik; Carmen Llerena; Knut E A Lundin; Sheraz Yaqub; Jørgen Jahnsen; Jeffrey J Gray; Jamie Rossjohn; Ludvig M Sollid; Inger Sandlie; Geir Åge Løset
Journal:  Sci Immunol       Date:  2021-08-20

3.  Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Authors:  Ariel E Marciscano; Ali Ghasemzadeh; Thomas R Nirschl; Debebe Theodros; Christina M Kochel; Brian J Francica; Yuki Muroyama; Robert A Anders; Andrew B Sharabi; Esteban Velarde; Wendy Mao; Kunal R Chaudhary; Matthew G Chaimowitz; John Wong; Mark J Selby; Kent B Thudium; Alan J Korman; David Ulmert; Daniel L J Thorek; Theodore L DeWeese; Charles G Drake
Journal:  Clin Cancer Res       Date:  2018-06-13       Impact factor: 12.531

Review 4.  The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.

Authors:  Sylvia Annabel Dass; Rehasri Selva Rajan; Gee Jun Tye; Venugopal Balakrishnan
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

5.  Bispecific antibodies targeting mutant RAS neoantigens.

Authors:  Jacqueline Douglass; Emily Han-Chung Hsiue; Brian J Mog; Michael S Hwang; Sarah R DiNapoli; Alexander H Pearlman; Michelle S Miller; Katharine M Wright; P Aitana Azurmendi; Qing Wang; Suman Paul; Annika Schaefer; Andrew D Skora; Marco Dal Molin; Maximilian F Konig; Qiang Liu; Evangeline Watson; Yana Li; Michael B Murphy; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Sandra B Gabelli; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Sci Immunol       Date:  2021-03-01

6.  Targeting a neoantigen derived from a common TP53 mutation.

Authors:  Emily Han-Chung Hsiue; Katharine M Wright; Jacqueline Douglass; Michael S Hwang; Brian J Mog; Alexander H Pearlman; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Qing Wang; Annika Schaefer; Michelle S Miller; Andrew D Skora; P Aitana Azurmendi; Michael B Murphy; Qiang Liu; Evangeline Watson; Yana Li; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; Shibin Zhou
Journal:  Science       Date:  2021-03-01       Impact factor: 47.728

7.  TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection.

Authors:  Zhan Zhou; Xingzheng Lyu; Jingcheng Wu; Xiaoyue Yang; Shanshan Wu; Jie Zhou; Xun Gu; Zhixi Su; Shuqing Chen
Journal:  R Soc Open Sci       Date:  2017-04-05       Impact factor: 2.963

8.  The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.

Authors:  Ying Shen; Yi-Ming Li; Jing-Jing Zhou; Zhan Zhou; Ying-Chun Xu; Wen-Bin Zhao; Shu-Qing Chen
Journal:  Int J Mol Sci       Date:  2019-08-12       Impact factor: 5.923

9.  Direct Detection and Quantification of Neoantigens.

Authors:  Qing Wang; Jacqueline Douglass; Michael S Hwang; Emily Han-Chung Hsiue; Brian J Mog; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Bert Vogelstein
Journal:  Cancer Immunol Res       Date:  2019-09-16       Impact factor: 11.151

Review 10.  Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Authors:  Shu-Juan Zhou; Jia Wei; Shu Su; Fang-Jun Chen; Yu-Dong Qiu; Bao-Rui Liu
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.